MedPath

PolyMedix, Inc.

PolyMedix, Inc. logo
🇺🇸United States
Ownership
Private
Established
2002-01-01
Employees
11
Market Cap
-
Website
http://www.polymedix.com

Clinical Trials

3

Active:1
Completed:1

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Phase 2
Terminated
Conditions
Percutaneous Coronary Intervention
Coronary Artery Disease (CAD)
Angioplasty
Interventions
First Posted Date
2011-03-11
Last Posted Date
2012-05-17
Lead Sponsor
PolyMedix, Inc.
Target Recruit Count
17
Registration Number
NCT01312935

Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus

Phase 2
Completed
Conditions
Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA)
(Susceptible or Methicillin Resistant)
Interventions
Drug: PMX-30063-investigational drug
First Posted Date
2010-09-29
Last Posted Date
2012-05-17
Lead Sponsor
PolyMedix, Inc.
Target Recruit Count
215
Registration Number
NCT01211470
Locations
🇷🇺

11 Sites, Multiple, Russian Federation

🇺🇦

5 Sites, Multiple, Ukraine

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.